Inside Precision Medicine, one of the world’s leading precision medicine publications, quoted our CEO and Co-founder Mohan Uttarwar as a key expert voice in an in-depth feature on how AI is reshaping drug discovery and development.
Mohan was featured alongside the CEO of Insilico Medicine and senior leadership from the Critical Path Institute, sharing his insights on how AI and multi-omics data from live circulating tumor cells are accelerating target identification, longitudinal disease tracking, and translational research with the potential to reduce drug development timelines from over a decade to just three to five years, and costs from billions to hundreds of millions of dollars.
Media Coverage
Read the full article on inside precision medicine here –